Compare Novavax Inc (NVAX) vs UBS Group AG Registered Ordinary Shares (UBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs UBS Group AG Registered Ordinary Shares — how do they compare? Novavax Inc trades at $11 (market cap $1.85B), while UBS Group AG Registered Ordinary Shares trades at $46.92 (market cap $144.63B). The key difference: UBS Group AG Registered Ordinary Shares is far larger — about 78.2× Novavax Inc's market cap, and UBS Group AG Registered Ordinary Shares pays a 2.32% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and UBS Group AG Registered Ordinary Shares for 0 Days on average.
| NVAX | UBS | |
|---|---|---|
Market Cap | $1.85B | $144.63B |
Volume | 8,362,562 | 1,746,723 |
Sector | Health | Financials |
52-Week High | $12.56 | $55.72 |
52-Week Low | $6.22 | $36.41 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $1.43B | $311.50B |
Dividend Yield | — | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 2.74% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported strong revenue of $1.12B in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Recent news highlights the company's pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in major markets.
Investment outlook remains speculative with analyst consensus heavily favoring Buy ratings (73.92%) but fundamental risks persist including negative cash flow trends and high debt levels. The stock offers potential upside from partnership expansions but faces significant execution and competitive risks in the biopharma sector.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About UBS Group AG Registered Ordinary Shares
UBS is a global financial services company focused on wealth management, investment banking, and asset management. It serves private, corporate, and institutional clients.
Read more on UBS →
